Olsson G, Lubsen J, van Es G A, Rehnqvist N
Br Med J (Clin Res Ed). 1986 Jun 7;292(6534):1491-3. doi: 10.1136/bmj.292.6534.1491.
A double blind randomised study of 154 patients with myocardial infarction assigned to metoprolol (100 mg twice daily) and 147 assigned to placebo compared the effects of treatment in relation to health state over three years. Health state was evaluated by a new method based on the average number of days spent in each of seven mutually exclusive categories of health. The scale took into account death, history of serious complications, functional state, and side effects of treatment. Of the maximum attainable 1095 days alive during the three years patients given metoprolol attained 992 days and those given placebo 964 days. During the period alive the metoprolol treated group spent an average of 278 days in an optimal functional state as compared with 176 days for the placebo treated group. This included 221 and 156 days respectively in a completely asymptomatic state (that is, without either cardiac symptoms or side effects of treatment). The time spent with a serious non-fatal complication was shortened by 56 days in the metoprolol group. The overall differences between the groups were statistically significant (p = 0.03). Aside from bringing an improved quality of life after myocardial infarction, metoprolol may add up to one month to life expectancy for three years of treatment.
一项针对154例心肌梗死患者的双盲随机研究，将患者分为美托洛尔组（每日两次，每次100毫克）和147例安慰剂组，比较了三年治疗期内治疗对健康状况的影响。健康状况通过一种新方法进行评估，该方法基于在七个相互排斥的健康类别中每个类别所花费的平均天数。该量表考虑了死亡、严重并发症史、功能状态和治疗副作用。在三年中，美托洛尔组患者在可达到的最长1095天存活期内达到了992天，而安慰剂组为964天。在存活期间，美托洛尔治疗组平均有278天处于最佳功能状态，而安慰剂治疗组为176天。这分别包括221天和156天处于完全无症状状态（即没有心脏症状或治疗副作用）。美托洛尔组发生严重非致命并发症的时间缩短了56天。两组之间的总体差异具有统计学意义（p = 0.03）。除了改善心肌梗死后的生活质量外，美托洛尔治疗三年可能使预期寿命延长多达一个月。
